120 related articles for article (PubMed ID: 38862868)
21. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
[TBL] [Abstract][Full Text] [Related]
22. Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice.
Iacuzzo C; Giudici F; Scomersi S; Ceccherini R; Zanconati F; Generali D; Bortul M
Breast Cancer Res Treat; 2021 Jun; 187(2):455-465. PubMed ID: 33646494
[TBL] [Abstract][Full Text] [Related]
23. The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience.
Shah S; Shaing C; Khatib J; Lodrigues W; Dreadin-Pulliam J; Anderson BB; Unni N; Farr D; Li HC; Sadeghi N; Syed S
Clin Breast Cancer; 2022 Dec; 22(8):823-827. PubMed ID: 36089460
[TBL] [Abstract][Full Text] [Related]
24. Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
Pece S; Sestak I; Montani F; Tillhon M; Maisonneuve P; Freddi S; Chu K; Colleoni M; Veronesi P; Disalvatore D; Viale G; Buus R; Cuzick J; Dowsett M; Di Fiore PP
Eur J Cancer; 2022 Mar; 164():52-61. PubMed ID: 35172273
[TBL] [Abstract][Full Text] [Related]
25. Genomic prediction of locoregional recurrence after mastectomy in breast cancer.
Cheng SH; Horng CF; West M; Huang E; Pittman J; Tsou MH; Dressman H; Chen CM; Tsai SY; Jian JJ; Liu MC; Nevins JR; Huang AT
J Clin Oncol; 2006 Oct; 24(28):4594-602. PubMed ID: 17008701
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC; Tausch C; Dedes KJ; Rochlitz C; Zimmermann S; von Moos R; Winterhalder R; Ruhstaller T; Mueller A; Buser K; Borner M; Novak U; Nussbaum CU; Seifert B; Bigler M; Bize V; Vilei SB; Rageth C; Aebi S;
BMC Cancer; 2017 Apr; 17(1):265. PubMed ID: 28407750
[TBL] [Abstract][Full Text] [Related]
27. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.
Kreike B; Halfwerk H; Armstrong N; Bult P; Foekens JA; Veltkamp SC; Nuyten DS; Bartelink H; van de Vijver MJ
Clin Cancer Res; 2009 Jun; 15(12):4181-90. PubMed ID: 19470741
[TBL] [Abstract][Full Text] [Related]
28. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer.
Albert JM; Gonzalez-Angulo AM; Guray M; Sahin A; Tereffe W; Woodward WA; Strom EA; Hunt KK; Tucker SL; Buchholz TA
Cancer; 2011 Apr; 117(8):1595-601. PubMed ID: 21472707
[TBL] [Abstract][Full Text] [Related]
29. Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients.
Pan B; Xu Y; Yao R; Cao X; Zhou X; Hao Z; Zhang Y; Wang C; Shen S; Luo Y; Zhu Q; Ren X; Kong L; Zhou Y; Sun Q
J Transl Med; 2023 Nov; 21(1):798. PubMed ID: 37946210
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Stavridi F; Kalogeras KT; Pliarchopoulou K; Wirtz RM; Alexopoulou Z; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2016; 11(10):e0164013. PubMed ID: 27695115
[TBL] [Abstract][Full Text] [Related]
31. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Bianchini G; Pusztai L; Karn T; Iwamoto T; Rody A; Kelly C; Müller V; Schmidt S; Qi Y; Holtrich U; Becker S; Santarpia L; Fasolo A; Del Conte G; Zambetti M; Sotiriou C; Haibe-Kains B; Symmans WF; Gianni L
Breast Cancer Res; 2013; 15(5):R86. PubMed ID: 24060333
[TBL] [Abstract][Full Text] [Related]
32. Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer.
Bense RD; Qiu SQ; de Vries EGE; Schröder CP; Fehrmann RSN
Cancer Treat Rev; 2018 Nov; 70():118-126. PubMed ID: 30149225
[TBL] [Abstract][Full Text] [Related]
33. Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest
Naoi Y; Tsunashima R; Shimazu K; Oikawa M; Imanishi S; Koyama H; Kamada Y; Ishihara K; Suzuki M; Osako T; Kinoshita T; Suto A; Nakamura S; Tsuda H; Noguchi S
Oncol Lett; 2023 May; 25(5):209. PubMed ID: 37123024
[TBL] [Abstract][Full Text] [Related]
34. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.
Valachis A; Mamounas EP; Mittendorf EA; Hayashi N; Ishitobi M; Natoli C; Fitzal F; Rubio IT; Tiezzi DG; Shin HC; Anderson SJ; Hunt KK; Matsuda N; Ohsumi S; Totomi A; Nilsson C
Cancer; 2018 Jul; 124(14):2923-2930. PubMed ID: 29723396
[TBL] [Abstract][Full Text] [Related]
36. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T; Masuda H; Cheng YC; Yang F; Sahin AA; Naoi Y; Matsunaga Y; Raghavendra A; Sinha AK; Fernandez JRE; James A; Yamagishi K; Matsushima T; Schuetz R; Tripathy D; Tada S; Jackson RS; Noguchi S; Nakamura S; Acoba JD; Ueno NT
Breast Cancer Res Treat; 2021 Sep; 189(2):455-461. PubMed ID: 34131830
[TBL] [Abstract][Full Text] [Related]
37. Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer.
Naoi Y; Saito Y; Kishi K; Shimoda M; Kagara N; Miyake T; Tanei T; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2019 Dec; 42(6):2680-2685. PubMed ID: 31638234
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
39. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.
Wang DY; Done SJ; McCready DR; Boerner S; Kulkarni S; Leong WL
Breast Cancer Res; 2011 Sep; 13(5):R92. PubMed ID: 21939527
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]